Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US
For patients with metastatic, persistent, and recurrent cervical cancer in the US, ABC was not as cost-effective as BC. Appropriate price reduction (10%) is recommended for atezolizumab to improve cost-effectiveness of ABC therapy.
Authors
- Yingtao Lin (ORCID: https://orcid.org/0000-0001-9168-0491)
- Yuanqing Huang (ORCID: https://orcid.org/0009-0009-5883-2946)
- Chang Wang (ORCID: https://orcid.org/0000-0002-9410-1878)
- Jian Chen (ORCID: https://orcid.org/0000-0002-1694-7763)
- C Li
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.3389/fimmu.2024.1481584
- Citations
- 4
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Natural Science Foundation of Fujian Province